MarketCapExport financials
Ovid Therapeutics (OVID)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Ovid Therapeutics Income Statement 2025-2011 | OVID
Brief overview of income trends at Ovid Therapeutics
The figures are compared over a five-year interval. According to figures from Ovid Therapeutics, revenue changed from 12.6 million dollars to 7.3 million dollars over five years. Overall revenue changed by −42.5%, equal to an annualized rate of about −10.5%. The decline points to a contraction in the scale of the business.
The operating result measured by EBITDA moved from −81.1 million dollars to −42.2 million dollars, or +48%. Additional revenue translated efficiently into EBITDA. The EBITDA share of revenue changed from −643% to −581.4%. The increased EBITDA share is a positive sign.
The net financial result changed from −$81 million to −$17.4 million. The negative result improved without reaching break-even.
The market value of the business moved from $167 million to $299 million, or +79.4%. Market value supported the favorable financial trajectory.
Financial takeaway
The results present an uneven picture without one dominant signal. The financial profile benefits from a stronger final result and an improving EBITDA margin. The main areas of concern are limited operating profitability and weak sales momentum. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Ovid Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
299 M | 163 M | 221 M | 142 M | 186 M | 167 M | 135 M | 78.6 M | 161 M | - | - | - | - | - | - |
Shares |
130 M | 71 M | 70.6 M | 70.4 M | 67.5 M | 59.4 M | 39.2 M | 24.6 M | 19.3 M | - | - | - | - | - | - |
Historical Prices |
2.3 | 2.3 | 3.13 | 2.01 | 2.76 | 2.81 | 3.6 | 2.83 | 8.5 | - | - | - | - | - | - |
Net Income |
-17.4 M | -26.4 M | -52.3 M | -54.2 M | 123 M | -81 M | -60.5 M | -52 M | -64.8 M | -22.4 M | -13.2 M | - | - | - | - |
Revenue |
7.25 M | 566 K | 392 K | 1.5 M | 208 M | 12.6 M | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | 12.6 K | - | - | - | - | - | - | - | - | - |
Operating Income |
-42.4 M | -61.9 M | -59.3 M | -55.5 M | 124 M | -81.4 M | -61.4 M | -52.9 M | -65 M | -22.5 M | -13.2 M | - | - | - | - |
Interest Expense |
25 M | 35.5 M | 6.94 M | 1.38 M | -45.7 K | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-42.2 M | -61.3 M | -58.7 M | -55 M | 124 M | -81.1 M | -61.2 M | -52.8 M | -64.9 M | -22.5 M | -13.2 M | - | - | - | - |
Operating Expenses |
49.7 M | 62.5 M | 59.7 M | 57.1 M | 84.2 M | 94 M | 61.4 M | 52.9 M | 65 M | - | - | - | - | - | - |
General and Administrative Expenses |
24.1 M | 25.7 M | 31.1 M | 32.4 M | 37.2 M | 30.6 M | 19.3 M | 19.1 M | 15 M | 13 M | 6.58 M | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Ovid Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
130 M | 167 M | 71 M | 71.2 M | 71.1 M | 71.1 M | 71 M | 71 M | 70.9 M | 70.7 M | 70.7 M | 70.6 M | 70.5 M | 70.5 M | 70.5 M | 70.4 M | 70.4 M | 70.3 M | 70.4 M | 67.9 M | 67.8 M | 66.1 M | 65.7 M | 59.4 M | 55.6 M | 54.7 M | 54.7 M | 54.7 M | 54.7 M | 54.7 M | 24.7 M | 24.6 M | 24.6 M | 24.6 M | 24.6 M | 24.6 M | 18.1 M | 9.84 M | 9.84 M | 9.84 M | 9.84 M | 9.84 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-10.2 M | -17 M | - | -12.2 M | -4.68 M | -10.2 M | - | -14 M | 8.52 M | -11.7 M | - | -11.3 M | -12.4 M | -13.4 M | - | -12 M | -14.6 M | -16.1 M | - | -11.4 M | -15.8 M | 176 M | - | -16.4 M | -22.6 M | -20 M | -17 M | -16.6 M | -13.1 M | -13.8 M | -12.9 M | -13 M | -12.9 M | -13.2 M | -11 M | -9.36 M | -10.2 M | -34.2 M | -7.56 M | -5.78 M | -5.39 M | -3.68 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
6.27 M | - | - | 132 K | 6.27 M | 130 K | - | 173 K | 169 K | 148 K | - | 109 K | 75 K | 66 K | - | 11.1 K | - | 1.45 M | - | - | - | 208 M | - | 6.91 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-5.07 M | -17.8 M | - | -12.5 M | -5.07 M | -12.6 M | - | -13.2 M | -20.5 M | -17.4 M | - | -12 M | -14.2 M | -14.9 M | - | -12.8 M | -14.3 M | -16.3 M | - | -11.7 M | -14.3 M | 177 M | - | -16.4 M | -23.1 M | -20.3 M | - | -16.8 M | -13.3 M | -14.1 M | - | -13.2 M | -13.2 M | -13.4 M | - | -9.41 M | -10.3 M | -34.3 M | - | -5.81 M | -5.42 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
389 K | 858 K | - | 365 K | 389 K | 2.32 M | - | -780 K | 29 M | 5.72 M | - | 776 K | 1.76 M | 1.54 M | - | 836 K | -284 K | 209 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-5.04 M | -17.8 M | - | -12.5 M | -5.01 M | -12.4 M | - | -13.1 M | -20.4 M | -17.3 M | - | -11.9 M | -14.1 M | -14.7 M | - | -12.7 M | -14.2 M | -16.2 M | - | -11.5 M | -14.2 M | 177 M | - | -16.2 M | -23 M | -20.2 M | - | -16.6 M | -13.2 M | -14 M | - | -13.1 M | -13.2 M | -13.4 M | - | -9.35 M | -10.3 M | -34.2 M | - | -5.79 M | -5.4 M | 5.9 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
11.3 M | 17.8 M | - | 12.7 M | 11.3 M | 12.7 M | - | 13.4 M | 20.7 M | 17.6 M | - | 12.1 M | 14.2 M | 15 M | - | 12.8 M | 14.3 M | 17.7 M | - | 11.7 M | 14.3 M | 31.8 M | - | 23.3 M | 23.1 M | 20.3 M | 17.3 M | 16.8 M | 13.3 M | 14.1 M | 13.1 M | 13.2 M | 13.2 M | 13.4 M | 11 M | 9.41 M | 10.3 M | 34.3 M | 7.59 M | 5.82 M | 5.42 M | 3.71 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
4.88 M | 6.66 M | - | 6.78 M | 4.88 M | 6.02 M | - | 5.54 M | 8.1 M | 7.17 M | - | 6.8 M | 8.25 M | 8.34 M | - | 7.63 M | 8.26 M | 9.88 M | - | 6.76 M | 6.63 M | 15.6 M | - | 7.44 M | 7.11 M | 5.67 M | - | 5.17 M | 4.2 M | 4.72 M | - | 4.63 M | 5.09 M | 4.96 M | - | 3.51 M | 4.21 M | 2.98 M | - | 3.12 M | 3.65 M | 2.59 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Ovid Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Israel
Britain
Russia
China
France
Germany
Belgium
Canada
Bermuda
Danmark
